160 related articles for article (PubMed ID: 31734179)
1. Qualification of impurities based on metabolite data.
Weidolf L; Andersson T; Bercu JP; Brink A; Glowienke S; Harvey J; Hayes MA; Jacques P; Lu C; Manevski N; Muster W; Nudelman R; Ogilvie R; Ottosson J; Teasdale A; Trela B
Regul Toxicol Pharmacol; 2020 Feb; 110():104524. PubMed ID: 31734179
[TBL] [Abstract][Full Text] [Related]
2. Management of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development.
Harvey J; Fleetwood A; Ogilvie R; Teasdale A; Wilcox P; Spanhaak S
Regul Toxicol Pharmacol; 2017 Mar; 84():116-123. PubMed ID: 28038978
[TBL] [Abstract][Full Text] [Related]
3. Harmonized 3Rs-based non-mutagenic impurity qualification study designs developed using the results of an IQ consortium survey.
Mitra MS; Datta K; Hutchinson R; Nicolette JJ; Pettersen JC; Wegesser TC; Bercu JP
Regul Toxicol Pharmacol; 2021 Jun; 122():104895. PubMed ID: 33610610
[TBL] [Abstract][Full Text] [Related]
4. Analysis of non-mutagenic substances in the context of drug impurity assessment - Few are potent toxicants.
Hasselgren C; Kenyon M; Anger LT; Cornwell P; Watt E; Bercu J
Regul Toxicol Pharmacol; 2024 Jun; 150():105645. PubMed ID: 38761967
[TBL] [Abstract][Full Text] [Related]
5. New limits proposed for the management of non-mutagenic impurities.
Slikkerveer A; Doehr O; Claude N; Hutchinson R; Harvey J; Spanhaak S
Regul Toxicol Pharmacol; 2024 Jun; 150():105647. PubMed ID: 38777301
[TBL] [Abstract][Full Text] [Related]
6. Deriving acceptable limits for non-mutagenic impurities in medicinal products - Durational adjustments.
Kenyon MO; Martin M; Martin EA; Brandstetter S; Wegesser T; Greene N; Harvey J
Regul Toxicol Pharmacol; 2024 Jun; 150():105644. PubMed ID: 38761968
[TBL] [Abstract][Full Text] [Related]
7. Use of In Silico Methods for Regulatory Toxicological Assessment of Pharmaceutical Impurities.
Kovarich S; Cappelli CI
Methods Mol Biol; 2022; 2425():537-560. PubMed ID: 35188646
[TBL] [Abstract][Full Text] [Related]
8. Control Strategy for Small Molecule Impurities in Antibody-Drug Conjugates.
Gong HH; Ihle N; Jones MT; Kelly K; Kott L; Raglione T; Whitlock S; Zhang Q; Zheng J
AAPS PharmSciTech; 2018 Apr; 19(3):971-977. PubMed ID: 29302872
[TBL] [Abstract][Full Text] [Related]
9. Analytical advances in pharmaceutical impurity profiling.
Holm R; Elder DP
Eur J Pharm Sci; 2016 May; 87():118-35. PubMed ID: 26690047
[TBL] [Abstract][Full Text] [Related]
10. Overview of genotoxic impurities in pharmaceutical development.
Bercu JP; Dobo KL; Gocke E; McGovern TJ
Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
[TBL] [Abstract][Full Text] [Related]
11. International Conference on Harmonisation; revised guidance on Q3B(R) Impurities in New Drug Products; Availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2003 Nov; 68(220):64628-9. PubMed ID: 14619944
[TBL] [Abstract][Full Text] [Related]
12. Calculating qualified non-mutagenic impurity levels: Harmonization of approaches.
Graham JC; Powley MW; Udovic E; Glowienke S; Nicolette J; Parris P; Kenyon M; White A; Maisey A; Harvey J; Martin EA; Dowdy E; Masuda-Herrera M; Trejo-Martin A; Bercu J
Regul Toxicol Pharmacol; 2021 Nov; 126():105023. PubMed ID: 34363920
[TBL] [Abstract][Full Text] [Related]
13. Industrial approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products.
Pokar D; Rajput N; Sengupta P
Int J Pharm; 2020 Feb; 576():119018. PubMed ID: 31911117
[TBL] [Abstract][Full Text] [Related]
14. Metabolites in safety testing.
Robison TW; Jacobs A
Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
[TBL] [Abstract][Full Text] [Related]
15. Non-mutagenic impurities - Recent industry experience of using dose durational limits in drug development.
Lortie A; Martin EA; Arnot K
Regul Toxicol Pharmacol; 2024 Feb; 147():105559. PubMed ID: 38145838
[TBL] [Abstract][Full Text] [Related]
16. Determination of the impurities in drug products containing montelukast and in silico/in vitro genotoxicological assessments of sulfoxide impurity.
Emerce E; Cok I; Degim IT
Toxicol Lett; 2015 Oct; 238(2):90-9. PubMed ID: 26205398
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Extractable Elements from Elastomers.
Paskiet D; Kraft C; Tullo E; Hunter J; Zurbriggen D
PDA J Pharm Sci Technol; 2019; 73(1):83-91. PubMed ID: 30030347
[TBL] [Abstract][Full Text] [Related]
18. Impurity Qualification Toxicology Study for a 2'-O-Methoxyethyl-Modified Antisense Inhibitor in Mice.
Kim TW; Papagiannis C; Capaldi D; McPherson AK; Mahdi F; Luu N; Rodriguez AA; Hoffmaster C; Serota D; Henry SP
Nucleic Acid Ther; 2020 Feb; 30(1):14-21. PubMed ID: 31687889
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the genotoxic and carcinogenic risks of p-nitrophenol when it is present as an impurity in a drug product.
Eichenbaum G; Johnson M; Kirkland D; O'Neill P; Stellar S; Bielawne J; DeWire R; Areia D; Bryant S; Weiner S; Desai-Krieger D; Guzzie-Peck P; Evans DC; Tonelli A
Regul Toxicol Pharmacol; 2009 Oct; 55(1):33-42. PubMed ID: 19500632
[TBL] [Abstract][Full Text] [Related]
20. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]